WHITE PAPER: 
the future of monoclonal antibodies

According to BIS Research and Research and Markets, monoclonal antibodies (mAbs) are expected to make up just under half of the USD $22.7 billion biologics discovery market in 2025. Engineered or recombinant proteins including next generation antibody therapeutics are expected to contribute 3 billion to the market by 2025. This white paper discusses antibodies with a first Biologic Licence Application (BLA) approval by the US Food and Drug Administration (FDA) in 2018, predicts imminent FDA approvals, discusses the emerging trends, and touches upon the next generation of antibody therapeutics. Download the White Paper to find out more.

December 9-13, 2018

San Diego, CA

DOWNLOAD WHITE PAPER
Fix the following errors:
Hide